Oral fast-release solid dispersion-paradigm shift to nanoparticles

Recent Patents on Drug Delivery and Formulation

Volumn 5, Issue 3, 2011, Pages 227-243

  Wong, Tin W ^a  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

Drug dissolution; Nanoparticles; Solid dispersion

Indexed keywords

AMPHOTERICIN B; AZATHIOPRINE; CAMPTOTHECIN; CELECOXIB; CELLULOSE; CORTICOSTEROID; CYCLOSPORIN; DOXYCYCLINE; GLASS; GLIMEPIRIDE; GLIPIZIDE; GLUCOCORTICOID; GRISEOFULVIN; IGURATIMOD; INDOMETACIN; ITRACONAZOLE; KETOPROFEN; MACROGOL; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NANOPARTICLE; NAPROXEN; NIFEDIPINE; POLOXAMER; RAPAMYCIN; SOLID LIPID NANOPARTICLE; SULFADIMETHOXINE; TACROLIMUS; UNINDEXED DRUG;

ANALYTIC METHOD; ARTICLE; CRYSTALLIZATION; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; ELECTROSPINNING; EVAPORATION; EXTRUSION SPHERONIZATION; FREEZE DRYING; HOT MELT FLUID BED COATING; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; MELT EXTRUSION; MELTING POINT; MICELLIZATION; MICROEMULSION; MOLTEN DISPERSION ENCAPSULATION; NANOENCAPSULATION; NANONIZATION; NANOTECHNOLOGY; OXIDATION REDUCTION STATE; PARTICLE SIZE; PATENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SOLID DISPERSION; SPRAY CONGEALING; SPRAY DRYING; SUPERCRITICAL FLUID; THERMOSTABILITY; TRANSITION TEMPERATURE; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; HUMANS; NANOMEDICINE; NANOPARTICLES; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SUSPENSIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 80052824487     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221111797200542     Document Type: Article

References (128)

1. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971; 60: 1281-302.
2. Ford JL. The current status of solid dispersions. Pharm Acta Helv 1986; 61: 69-88.
3. Hajratwala BR. Dissolution of solid dispersion systems. Aust J Pharm Sci 1974; NS3: 101-9.
4. Craig DQM. Polyethylene glycols and drug release. Drug Dev Ind Pharm 1990; 16: 2501-26.
5. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 2002; 231: 131-44.
6. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000; 50: 47-60.
7. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today 2007; 12: 1068-75.
8. Ali W, Williams AC, Rawlinson CF. Stochiometrically governed molecular interactions in drug: Poloxamer solid dispersions. Int J Pharm 2010; 391: 162-8.
9. Torrado S, Torrado S, Torrado JJ, Cadórniga R. Preparation, dissolution and characterization of albendazole solid dispersions. Int J Pharm 1996; 140: 247-50.
10. Ren F, Jing Q, Tang Y, Shen Y, Chen J, Gao F, et al. Characteristics of bicalutamide solid dispersions and improvement of the dissolution. Drug Dev Ind Pharm 2006; 32: 967-72.
11. Saers ES, Nyström C, Aldén M. Physicochemical aspects of drug release. XVI. The effects of storage on drug dissolution from solid dispersions and the influence of cooling rate and incorporation of surfactant. Int J Pharm 1993; 90: 105-18.
12. Sjokvist E, Nystrom C, Alden M, Caram-Lelham N. Physicochemical aspects of drug release. XIV. The effects of some ionic and non-ionic surfactants on properties of a sparingly soluble drug in solid dispersions. Int J Pharm 1992; 79(2-3): 123-33.
13. Wang X, Michoel, A, Mooter GVD. Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int J Pharm 2005; 303: 54-61.
14. ®200 solid dispersions characterization, physical stability and in vivo performance. Eur J Pharm Sci 2009; 38: 270-78.
15. Zajc N, Obreza A, Bele M, Srcic S. Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method. Int J Pharm 2005; 291: 51-8.
16. Ho H-O, Su H-L, Tsai T, Sheu M-T. The preparation and characterization of solid dispersions on pellets using a fluidized-bed system. Int J Pharm 1996; 139: 223-9.
17. Fawaz F, Bonini F, Guyot M, Bildet J, Maury M, Lagueny AM. Bioavailability of norfloxacin from PEG 6000 solid dispersion and cyclodextrin inclusion complexes in rabbits. Int J Pharm 1996; 132: 271-5.
18. Okonogi S, Oguchi T, Yonemochi E, Puttipipatkhachorn S, Yamamoto K. Improved dissolution of ofloxacin via solid dispersion. Int J Pharm 1997; 156: 175-80.
19. Pokharkar VB, Mandpe LP, Padamwar MN, Ambike AA, Mahadik KR, Paradkar A. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol 2006; 167: 20-5.
20. Zerrouk N, Chemtob C, Arnaub P, Toscani S, Dugue J. In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. Int J Pharm 2001; 225: 49-62.
21. Al-Hamidi H, Edwards AA, Mohammad MA, Nokhodchi A. To enhance dissolution rate of poorly water-soluble drugs: Glucosamine hydrochloride as a potential carrier in solid dispersion formulations. Colloids and Surfaces B: Biointerfaces 2010; 76: 170-8.
22. Verheyen S, Blaton N, Kinget R, Van den Mooter G. Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. Int J Pharm 2002; 249: 45-58.
23. Franco M, Trapani G, Latrofa A, Tullio C, Provenzano MR, Serra M, et al. Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K30 solid dispersions. Int J Pharm 2001; 225: 63-73.
24. Betageri GV, Dipali SR. Preparation and in vitro dissolution profiles of tolazamide-polyethylene glycol solid dispersions. Drug Dev Ind Pharm 1995; 21: 1347-52.
25. Weuts I, Kempen D, Decorte A, Verreck G, Peeters J, Brewster M, et al. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64. Eur J Pharm Sci 2005; 25: 313-20.
26. Xie Y, Xie P, Song X, Tang X, Song H. Preparation of esomeprazole zinc solid dispersion and study on its pharmacokinetics. Int J Pharm 2008; 360:53-7.
27. ® 53/10 physical mixtures and solid dispersions. Int J Pharm 1995; 126: 287-91.
28. Marín MT, Margarit MV, Salcedo GE. Characterization and solubility study of solid dispersions of flunarizine and polyvinylpyrrolidone. IL Farmaco 2002; 57: 723-7.
29. Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 2008; 70: 493-9.
30. Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm 2007; 66: 334-47.
31. Kim E-J, Chun M-K, Jang J-S, Lee I-H, Lee K-R, Choi H-K. Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur J Pharm Biopharm 2006; 64: 200-5.
32. Karavas E, Ktistis G, Xenakis A, Georgarakis E. Miscibility behaviour and formation mechanism of stabilized felodipinepolyvinylpyrrolidone amorphous solid dispersions. Drug Dev Ind Pharm 2005; 31: 473-89.
33. Tran TT-D, Tran PH-L, Choi H-G, Han H-K, Lee B-J. The roles of acidifiers in solid dispersions and physical mixtures. Int J Pharm 2010; 384: 60-6.
34. Yippagunta SR, Maul KA, Tallavajhala S, Grant DJW. Solid-state characterization of nifedipine solid dispersions. Int J Pharm 2002; 236: 111-23.
35. Chutimaworapan S, Ritthidej GC, Yonemochi E, Oguchi T, Yamamoto K. Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions. Drug Dev Ind Pharm 2000; 26: 1141-50.
36. Okimoto K, Miyake M, Ibuki R, Yasumura M, Ohnishi N, Nakai T. Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose. Int J Pharm 1997; 159: 85-93.
37. Smikalla MM, Urbanetz NA. The influence of povidone K17 on the storage stability of solid dispersions of nimodipine and polyethylene glycol. Eur J Pharm Biopharm 2007; 66: 106-12.
38. Urbanetz NA. Stabilization of solid dispersions of nimodipine and polyethylene glycol. Eur J Pharm Sci 2006; 28: 67-76.
39. Tran PHL, Tran HTT, Lee B-J. Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J Control Release 2008; 129: 59-65.
40. Fini A, Moyano JR, Ginés JM, Perez-Martinez JI, Rabasco AM. Diclofenac salts, II. Solid dispersions in PEG6000 and Gelucire 50/13. Eur J Pharm Biopharm 2005; 60: 99-111.
41. Özkan Y, Do anay N, Dikmen N, Isimer A. Enhanced release of solid dispersions of etodolac in polyethylene glycol. IL Farmaco 2000; 55: 433-8.
42. Ozeki T, Yuasa H, Kanaya Y. Application of the solid dispersion method to the controlled release medicine. IX. Difference in the release of flurbiprofen from solid dispersions with poly(ethylene oxide) and hydroxypropylcellulose and the interaction between medicine and polymers. Int J Pharm 1997; 155: 209-17.
43. Newa M, Bhandari KH, Li DX, Kwon T-H, Kim JA, Yoo BK, et al. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int J Pharm 2007; 343: 228-37.
44. Gupta MK, Bogner RH, Goldman D, Tseng YC. Mechanism for further enhancement in drug dissolution from solid-dispersion granules upon storage. Pharm Dev Technol 2002; 7: 103-12.
45. Zahedi P, Lee PI. Solid molecular dispersions of poorly watersoluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels. Eur J Pharm Biopharm 2007; 65: 320-8.
46. Rouchotas C, Cassidy OE, Rowley G. Comparison of surface modification and solid dispersion techniques for drug dissolution. Int J Pharm 2000; 195: 1-6.
47. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm 1999; 181: 143-51.
48. Valizadeh H, Zakeri-Milani P, Barzegar-Jalali M, Mohammadi G, Danesh-Bahreini MA, Adibkia K, et al. Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev Ind Pharm 2007; 33: 45-56.
49. Nijlen TV, Brennan K, Mooter GVD, Blaton N, Kinget R, Augustijns P. Improvement of the dissolution rate of artemisinin by means of supercritical fluid technology and solid dispersions. Int J Pharm 2003; 254: 173-81.
50. Khoo S-M, Porter CJH, Charman WN. The formulation of halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: physical stability and absolute bioavailability assessment. Int J Pharm 2000; 205: 65-78.
51. Nepal PR, Han H-K, Choi H-K. Enhancement of solubility and dissolution of coenzyme Q10 using solid dispersion formulation. Int J Pharm 2010; 383: 147-53.
52. Rahman Z, Zidan AS, Khan MA. Risperidone solid dispersion for orally disintegrating tablet: Its formulation design and nondestructive methods of evaluation. Int J Pharm 2010; 400: 49-58.
53. Frontini R, Mielck JB. Interactions between bendroflumethiazide and water-soluble polymers. I. Solubility of bendroflumethiazide in water from solid dispersions and formation of associates under climatic stress. Eur J Pharm Biopharm 1997; 43: 185-91.
54. Shin S-C, Kim J. Physicochemical characterization of solid dispersion of furosemide with TPGS. Int J Pharm 2003; 251: 79-84.
55. Arias MJ, Ginés JM, Moyano JR, Rabasco AM. Dissolution properties and in vivo behaviour of triamterene in solid dispersions with polyethylene glycols. Pharm Acta Helv 1996; 71: 229-35.
56. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 2003; 267: 79-91.
57. Mooter GVD, Augustijns P, Blaton N, Kinget R. Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int J Pharm 1998; 164: 67-80.
58. Trapani G, Franco M, Latrofa A, Pantaleo MR, Provenzano MR, Sanna E, et al. Physicochemical characterization and in vivo properties of zolpidem in solid dispersions with polyethylene glycol 4000 and 6000. Int J Pharm 1999; 184: 121-30.
59. Damian F, Blaton N, Naesens L, Balzarini J, Kinget R, Augustijns P, et al. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur J Pharm Sci 2000; 10: 311-22.
60. ® 44/14 and PVP K30. Int J Pharm 2002; 244: 87-98.
61. Chen Y, Zhang GGZ, Neilly J, Marsh K, Mawhinney D, Sanzgiri YD. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Int J Pharm 2004; 286: 69-80.
62. Moneghini M, Kikic I, Voinovich D, Perissutti B, Filipovi Grcic J. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation and in vitro dissolution. Int J Pharm 2001; 222: 129-38.
63. Huang J, Wigent RJ, Bentzley CM, Schwartz JB. Nifedipine solid dispersion in microparticles of ammonio methacrylate copolymer and ethylcellulose binary blend for controlled drug delivery: Effect of drug loading on release kinetics. Int J Pharm 2006; 319: 44-54.
64. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. Solid dispersion particles of tolbutamide prepared with fine silica particles by the spray-drying method. Powder Technol 2004; 141: 187-95.
65. Jachowicz R, Nurnberg E, Pieszczek B, Kluczykowska B, Maciejewska A. Solid dispersion of ketoprofen in pellets. Int J Pharm 2000; 206: 13-21.
66. Sethia S, Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int J Pharm 2004; 272: 1-10.
67. Won D-H, Kim M-S, Lee S, Park J-S, Hwang S-J. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int J Pharm 2005; 301: 199-208.
68. Liu C, Wu J, Shi B, Zhang Y, Gao T, Pei Y. Enhancing the bioavailability of cyclosporine A using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm 2006; 32: 115-23.
69. Nurulaini H, Wong TW. Design of in-situ dispersible and calcium crosslinked alginate pellets as intestinal-specific drug carrier by melt pelletization technique. J Pharm Sci 2011; 100: 2248-57.
70. nd Edition. USA: Marcel Dekker 2005: 154 (Chap 13): 385-406.
71. Vilhelmsen T, Eliasen H, Schæfer T. Effect of a melt agglomeration process on agglomerates containing solid dispersions. Int J Pharm 2005; 303: 132-42.
72. Seo A, Holm P, Kristensen HG, Schæfer T. The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer. Int J Pharm 2003; 259: 161-71.
73. Passerini N, Albertini B, Gonzalez-Rodriguez ML, Cavallaria C, Rodriguez L. Preparation and characterisation of ibuprofenpoloxamer 188 granules obtained by melt granulation. Eur J Pharm Sci 2002; 15: 71-8.
74. Verreck G, Decorte A, Heymans K, Adriaensen J, Cleeren D, Jacobs A, et al. The effect of pressurized carbon dioxide as a temporary plasticizer and foaming agent on the hot stage extrusion process and extrudate properties of solid dispersions of itraconazole with PVP-VA 64. Eur J Pharm Sci 2005; 26: 349-58.
75. Perissutti B, Newton JM, Podczeck F, Rubessa F. Preparation of extruded carbamazepine and PEG 4000 as a potential rapid release dosage form. Eur J Pharm Biopharm 2002; 53: 125-32.
76. Shibata Y, Fujii M, Sugamura Y, Yoshikawa R, Fujimoto S, Nakanishi S, et al. The preparation of a solid dispersion powder of indomethacin with crospovidone using a twin-screw extruder or kneader. Int J Pharm 2009; 365: 53-60.
77. Yunzhe S, Rui Y, Wenliang Z, Xing T. Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. Int J Pharm 2008; 359: 144-9.
78. Ghebremeskel AN, Vemavarapu C, Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Selection of polymer-surfactant combinations using solubility parameters and testing the processability. Int J Pharm 2007; 328: 119-29.
79. Mooter GVD, Weuts I, Ridder TD, Blaton N. Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int J Pharm 2006; 316:1-6.
80. ®, in the formulation of solid dispersions of itraconazole. Eur J Pharm Sci 2007; 30: 288-94.
81. Kennedy, JP, Niebergall, PJ. Development and optimization of a solid dispersion by hot-melt fluid bed coating method. Pharm Dev Technol 1996; 1(1): 51-62.
82. Fini A, Rodriguez L, Cavallari C, Albertini B, Passerini N. Ultrasound-compacted and spray-congealed indomethacin/polyethyleneglycol systems. Int J Pharm 2002; 247: 11-11.
83. Hasegawa S, Hamaura T, Furuyama N, Kusai A, Yoncmochi E, Terada K. Effects of water content in physical mixture and heating temperature on crystallinity of troglitazone-PVP K30 solid dispersions prepared by closed melting method. Int J Pharm 2005; 302: 103-12.
84. Moneghini M, Bellich B, Baxa P, Princivalle F. Microwave generated solid dispersions containing ibuprofen. Int J Pharm 2008; 361: 125-30.
85. Moneghini M, Zingone G, Zordi ND. Influence of the microwave technology on the physical-chemical properties of solid dispersion with nimesulide. Powder Technol. 2009: 195: 259-63.
86. Ker J, Srcic S, Kofler B. Alternative solvent-free preparation methods for felodipine surface solid dispersions. Drug Dev Ind Pharm 1998; 24: 359-63.
87. Fujii M, Okada H, Shibata Y, Teramachi H, Kondoh M, Watanabe Y. Preparation, characterization, and tableting of a solid dispersion of indomethacin with crospovidone. Int J Pharm 2005; 293: 145-53.
88. Joe JH, Lee WM, Park Y-J, Joe KH, Oh DH, Seo YG, et al. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus. Int J Pharm 2010; 395; 161-6.
89. Janssens S, Anné M, Rombaut P, Mooter GVD. Spray drying from complex solvent systems broadens the applicability of kollicoat IR as a carrier in the formulation of solid dispersions. Eur J Pharm Sci 2009; 37: 241-8.
90. Goddeeris C, Willems T, Mooter GVD. Formulation of fast disintegrating tablets of ternary solid dispersions consisting of TPGS1000 and HPMC 2910 or PVPVA 64 to improve the dissolution of the anti-HIV drug UC 781. Eur J Pharm Sci 2008; 34: 293-302.
91. Janssens S, Humbeeck JV, Mooter GVD. Evaluation of the formulation of solid dispersions by co-spray drying itraconazole with Inutec SP1, a polymeric surfactant, in combination with PVPVA 64. Eur J Pharm Biopharm 2008; 70: 500-5.
92. Goddeeris C, Willems T, Houthoofd K, Martens JA, Mooter GVD. Dissolution enhancement of the anti-HIV drug UC 781 by formulation in a ternary solid dispersion with TPGS 1000 and Eudragit E100. Eur J Pharm Biopharm 2008; 70: 861-8.
93. Weuts I, Kempen D, Verreck G, Peeters J, Brewster M, Blaton N, et al. Salt formation in solid dispersions consisting of polyacrylic acid as a carrier and three basic model compounds resulting in very high glass transition temperatures and constant dissolution properties upon storage. Eur J Pharm Sci 2005; 25: 387-93.
94. Weuts I, Kempen D, Verreck G, Decorte A, Heymans K, Peeters J, et al. Study of the physicochemical properties and stability of solid dispersions of loperamide and PEG6000 prepared by spray drying. Eur J Pharm Biopharm 2005; 59: 119-26.
95. Paradkar A, Ambike AA, Jadhav BK, Mahadik KR. Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int J Pharm 2004; 271: 281-6.
96. Orienti I, Bigucci F, Luppi B, Cerchiara T, Zuccari G, Giunchedi P, et al. Polyvinylalcohol substituted with triethyleneglycolmonoethylether as a new material for preparation of solid dispersions of hydrophobic drugs. Eur J Pharm Biopharm 2002; 54: 229-33.
97. Muhrer G, Meier U, Fusaro F, Albano S, Mazzotti M. Use of compressed gas precipitation to enhance the dissolution behaviour of a poorly water-soluble drug: Generation of drug microparticles and drug-polymer solid dispersions. Int J Pharm 2006; 308: 69-83.
98. Badens E, Majerik V, Horváth G, Szokonya L, Bosc N, Teillaud E, et al. Comparison of solid dispersions produced by supercritical antisolvent and spray-freezing technologies. Int J Pharm 2009; 377:25-34.
99. Brion M, Jaspart S, Perrone L, Piel G, Evrard B. The supercritical micronization of solid dispersions by particles from gas saturated solutions using experimental design. J Supercritical Fluids 2009; 51: 50-6.
100. Overhoff KA, Moreno A, Miller DA, Johnston KP, Williams III RO. Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing. Int J Pharm 2007; 336: 122-32.
101. Srinarong P, Faber JH, Visser MR, Hinrichs WLJ, Frijlink HW. Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants. Eur J Pharm Biopharm 2009; 73: 154-61.
102. Sun N, Wei X, Wu B, Chen J, Lu Y, Wu W. Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powder Technol 2008; 182: 71-80.
103. Zhang X, Sun N, Wu B, Lu Y, Guan T, Wu W. Physical characterization of lansoprazole/PVP solid dispersion prepared by fluidbed coating technique. Powder Technol 2008; 182: 480-5.
104. Yu D-G, Yang J-M, Branford-White C, Lu P, Zhang L, Zhu L-M. Third generation solid dispersions of ferulic acid in electrospun composite nanofibers. Int J Pharm 2010; 400: 158-64.
105. Saito M, Ugajin T, Nozawa Y, Sadzuka Y, Miyagishima A, Sonobe T. Preparation and dissolution characteristics of griseofulvin solid dispersions with saccharides. Int J Pharm 2002; 249: 71-9.
106. Mooter GVD, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P, et al. Physical stabilization of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci 2001; 12: 261-9.
107. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm 2005; 293: 155-64.
108. Chauhan B, Shimpi S, Paradkar A. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur J Pharm Sci 2005; 26: 219-30.
109. Miller, W.K. Nanoparticles comprising drug: A non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate. US20100183731 (2010).
110. Bloom, C.J., Crew, M.D., Friesen, D.T., Miller, W.K., Morgen, M.M., Smithey, DT. Nanoparticles comprising ionisable poorly water soluble cellulosic polymers. US20100215747 (2010).
111. Bloom, C.J., Crew, M.D., Miller, W.K., Smithey, D.T. Nanoparticles comprising a non-ionisable polymer and an anionic cellulosic polymer. US20100266692 (2010).
112. Miller, W.K., Smithey, D., Frankamp, B.L., Tadday, R. Pharmaceutical compositions comprising nanoparticles and a resuspending material. US20100310663 (2010).
113. Doney, J.A., Brzeczko, A.W., Shores, C.S. Amorphous ezetimibe and the production thereof. US20080085315 (2008).
114. Kang, H.W., Yim, E.Y., Seo, M.H. Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof. US20100008998 (2010).
115. Moschwitzer J.P. Embeded micellar nanoparticles. US20090035368 (2009).
116. Uchegbu, I.F., Schatzlein, A.G., Hou, X. Polymeric micellar clusters and their uses in formulating drugs. US20100159014 (2010).
117. Li, P., Pudipeddi, M., Royce, A.E., Hynes, S.R., Serajuddin, A.T.M., Ambuhl, M., Luckel, B. Spontaneously dispersible pharmaceutical composition. US20080064760 (2008).
118. Spengler, E.G., Dahms, G.H. Composition and method employing membrane structured solid nanoparticles for enhanced delivery of oral care actives. US20060024248 (2006).
119. Raheja, P., Kaushik, A., Gandhi, R., Singh, R.B., Mathur, R.S. Sirolimus nanodispersion. US20080138405 (2008).
120. Jain, R.A., Ruddy, S.B., Cumming, K.L., Clancy, M.J.A., Codd, J.E. Rapid disintegrating solid oral dosage form. US20080213371 (2008).
121. Jenkins, S., Liversidge, G., Liversidge, E. Nanoparticulate tacrolimus formulations. US20080152720 (2008).
122. Galli, C.J., Lodaya, M.P., Mollan, M.J., Polak, W.M., Shah, U., Vemavarapu, C. Preparation of pharmaceutical compositions containing nanoparticles. US20070020197 (2007).
123. Kubo, Y., Yamakawa, T., Yamasaki, Y. Fine dispersion of sparingly soluble drug and process for producing the same. US20070224282 (2007).
124. Suzuki, H., Yoshinari, T., Nagaoka, N. Finely divided composition containing poorly water soluble substance. US20080118552 (2008).
125. Jiang, Y., Jiang, Z. Method for the prpeparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound. US20100151037 (2010).
126. Payne, T., Meiser, F., Postma, A., Cammarano, R., Williams, J., McCormick, P., Dodd, A., Caruso, F. Nanoparticle composition and methods of synthesis thereof. US20090028948 (2009).
127. Wikipedia. Lopinavir/ritonavir. http://en.wikipedia.org/wiki/Kaletra (24 June 2011).
128. Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-96.